Nurix Therapeutics Statistics
Total Valuation
NRIX has a market cap or net worth of $2.84 billion. The enterprise value is $1.86 billion.
| Market Cap | 2.84B |
| Enterprise Value | 1.86B |
Important Dates
The last earnings date was Monday, October 12, 2026, after market close.
| Earnings Date | Oct 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NRIX has 109.25 million shares outstanding. The number of shares has increased by 32.80% in one year.
| Current Share Class | 109.25M |
| Shares Outstanding | 109.25M |
| Shares Change (YoY) | +32.80% |
| Shares Change (QoQ) | +4.56% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 83.82% |
| Float | 79.58M |
Valuation Ratios
The trailing PE ratio is 9.68 and the forward PE ratio is 7.04.
| PE Ratio | 9.68 |
| Forward PE | 7.04 |
| PS Ratio | 4.05 |
| Forward PS | 8.54 |
| PB Ratio | 2.93 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | 7.69 |
| P/OCF Ratio | 7.49 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.25, with an EV/FCF ratio of 5.03.
| EV / Earnings | 6.31 |
| EV / Sales | 2.65 |
| EV / EBITDA | 6.25 |
| EV / EBIT | 6.42 |
| EV / FCF | 5.03 |
Financial Position
The company has a current ratio of 8.44, with a Debt / Equity ratio of 0.07.
| Current Ratio | 8.44 |
| Quick Ratio | 8.19 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.18 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 43.99% and return on invested capital (ROIC) is 21,082.05%.
| Return on Equity (ROE) | 43.99% |
| Return on Assets (ROA) | 21.08% |
| Return on Invested Capital (ROIC) | 21,082.05% |
| Return on Capital Employed (ROCE) | 27.21% |
| Weighted Average Cost of Capital (WACC) | 13.94% |
| Revenue Per Employee | $2.21M |
| Profits Per Employee | $930,211 |
| Employee Count | 317 |
| Asset Turnover | 0.82 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NRIX has paid $13.34 million in taxes.
| Income Tax | 13.34M |
| Effective Tax Rate | 4.33% |
Stock Price Statistics
The stock price has increased by +150.43% in the last 52 weeks. The beta is 1.82, so NRIX's price volatility has been higher than the market average.
| Beta (5Y) | 1.82 |
| 52-Week Price Change | +150.43% |
| 50-Day Moving Average | 25.09 |
| 200-Day Moving Average | 19.91 |
| Relative Strength Index (RSI) | 63.96 |
| Average Volume (20 Days) | 2,453,474 |
Short Selling Information
The latest short interest is 17.66 million, so 16.16% of the outstanding shares have been sold short.
| Short Interest | 17.66M |
| Short Previous Month | 17.98M |
| Short % of Shares Out | 16.16% |
| Short % of Float | 22.19% |
| Short Ratio (days to cover) | 11.33 |
Income Statement
In the last 12 months, NRIX had revenue of $701.94 million and earned $294.88 million in profits. Earnings per share was $2.69.
| Revenue | 701.94M |
| Gross Profit | 367.86M |
| Operating Income | 289.66M |
| Pretax Income | 308.21M |
| Net Income | 294.88M |
| EBITDA | 297.77M |
| EBIT | 289.66M |
| Earnings Per Share (EPS) | $2.69 |
Balance Sheet
The company has $1.05 billion in cash and $65.33 million in debt, with a net cash position of $982.92 million or $9.00 per share.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 65.33M |
| Net Cash | 982.92M |
| Net Cash Per Share | $9.00 |
| Equity (Book Value) | 968.31M |
| Book Value Per Share | 8.87 |
| Working Capital | 972.95M |
Cash Flow
In the last 12 months, operating cash flow was $379.31 million and capital expenditures -$9.50 million, giving a free cash flow of $369.81 million.
| Operating Cash Flow | 379.31M |
| Capital Expenditures | -9.50M |
| Depreciation & Amortization | 8.11M |
| Net Borrowing | n/a |
| Free Cash Flow | 369.81M |
| FCF Per Share | $3.38 |
Margins
Gross margin is 52.41%, with operating and profit margins of 41.27% and 42.01%.
| Gross Margin | 52.41% |
| Operating Margin | 41.27% |
| Pretax Margin | 43.91% |
| Profit Margin | 42.01% |
| EBITDA Margin | 42.42% |
| EBIT Margin | 41.27% |
| FCF Margin | 52.68% |
Dividends & Yields
NRIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -32.80% |
| Shareholder Yield | -32.80% |
| Earnings Yield | 10.33% |
| FCF Yield | 13.01% |
Analyst Forecast
The average price target for NRIX is $34.50, which is 32.59% higher than the current price. The consensus rating is "Buy".
| Price Target | $34.50 |
| Price Target Difference | 32.59% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 55.86% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NRIX has an Altman Z-Score of 6.13 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.13 |
| Piotroski F-Score | 7 |